OBJECTIVES: The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors ("statins") have anti-inflammatory properties and are associated with improved outcomes in critically ill patients. We investigated whether previous statin therapy affects outcomes in patients at risk for acute respiratory distress syndrome. DESIGN: Patients were followed-up for the primary outcome of acute respiratory distress syndrome and secondary outcomes of intensive care unit and 60-day mortality, organ dysfunction, and ventilator-free days in a secondary analysis of a prospective cohort study. Receipt of statin therapy was recorded. Propensity score matching was used to adjust for confounding by indication. SETTING: Intensive care units at a tertiary care academic medical center. PATIENTS: Critically ill patients (2,743) with acute respiratory distress syndrome risk factors. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Acute respiratory distress syndrome developed in 738 (26%) patients; 413 patients (15%) received a statin within 24 hrs of intensive care unit admission. Those who had received a statin within 24 hrs had a lower rate of development of acute respiratory distress syndrome (odds ratio 0.56; 95% confidence interval 0.43-0.73; p<.0001). After multivariate adjustment for potential confounders, this association remained significant (odds ratio 0.69; 95% confidence interval 0.51-0.92; p=.01). However, after propensity score matching, the association was not statistically significant (odds ratio 0.79; 95% confidence interval 0.57-1.10; p=.16). Statin use was not associated with reduced acute respiratory distress syndrome mortality, organ dysfunction, or ventilator-free days. Results of the study were presented in accordance with STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines. CONCLUSIONS: Statin therapy at the time of intensive care unit admission was not associated with a lower rate of development of acute respiratory distress syndrome after matching for patient propensity to receive statins. Statin therapy was not associated with improvements in acute respiratory distress syndrome mortality, organ failure, or days free from mechanical ventilation.
OBJECTIVES: The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors ("statins") have anti-inflammatory properties and are associated with improved outcomes in critically illpatients. We investigated whether previous statin therapy affects outcomes in patients at risk for acute respiratory distress syndrome. DESIGN:Patients were followed-up for the primary outcome of acute respiratory distress syndrome and secondary outcomes of intensive care unit and 60-day mortality, organ dysfunction, and ventilator-free days in a secondary analysis of a prospective cohort study. Receipt of statin therapy was recorded. Propensity score matching was used to adjust for confounding by indication. SETTING: Intensive care units at a tertiary care academic medical center. PATIENTS: Critically illpatients (2,743) with acute respiratory distress syndrome risk factors. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS:Acute respiratory distress syndrome developed in 738 (26%) patients; 413 patients (15%) received a statin within 24 hrs of intensive care unit admission. Those who had received a statin within 24 hrs had a lower rate of development of acute respiratory distress syndrome (odds ratio 0.56; 95% confidence interval 0.43-0.73; p<.0001). After multivariate adjustment for potential confounders, this association remained significant (odds ratio 0.69; 95% confidence interval 0.51-0.92; p=.01). However, after propensity score matching, the association was not statistically significant (odds ratio 0.79; 95% confidence interval 0.57-1.10; p=.16). Statin use was not associated with reduced acute respiratory distress syndrome mortality, organ dysfunction, or ventilator-free days. Results of the study were presented in accordance with STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines. CONCLUSIONS: Statin therapy at the time of intensive care unit admission was not associated with a lower rate of development of acute respiratory distress syndrome after matching for patient propensity to receive statins. Statin therapy was not associated with improvements in acute respiratory distress syndrome mortality, organ failure, or days free from mechanical ventilation.
Authors: M Alan Brookhart; Sebastian Schneeweiss; Kenneth J Rothman; Robert J Glynn; Jerry Avorn; Til Stürmer Journal: Am J Epidemiol Date: 2006-04-19 Impact factor: 4.897
Authors: Daryl J Kor; Remzi Iscimen; Murat Yilmaz; Michael J Brown; Daniel R Brown; Ognjen Gajic Journal: Intensive Care Med Date: 2009-01-31 Impact factor: 17.440
Authors: Holger C Müller; Katharina Hellwig; Simone Rosseau; Thomas Tschernig; Andreas Schmiedl; Birgitt Gutbier; Bernd Schmeck; Stefan Hippenstiel; Harm Peters; Lars Morawietz; Norbert Suttorp; Martin Witzenrath Journal: Crit Care Date: 2010-07-30 Impact factor: 9.097
Authors: Hemang Yadav; Ravi K Lingineni; Ericka J Slivinski; Katie A Stockler; Arun Subramanian; Gustavo S Oderich; Dennis A Wigle; Rickey E Carter; Daryl J Kor Journal: Anesth Analg Date: 2014-10 Impact factor: 5.108
Authors: Andrew S Allegretti; David J R Steele; Jo Ann David-Kasdan; Ednan Bajwa; John L Niles; Ishir Bhan Journal: Crit Care Date: 2013-06-20 Impact factor: 9.097